GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. ME...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Transl Med
Egile Nagusiak: Pietrantonio, Filippo, Berenato, Rosa, Maggi, Claudia, Caporale, Marta, Milione, Massimo, Perrone, Federica, Tamborini, Elena, Baratti, Dario, Kusamura, Shigeki, Mariani, Luigi, Niger, Monica, Mennitto, Alessia, Gloghini, Annunziata, Bossi, Ilaria, Settanni, Giulio, Busico, Adele, Bagnoli, Pietro Francesco, Di Bartolomeo, Maria, Deraco, Marcello, de Braud, Filippo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859944/
https://ncbi.nlm.nih.gov/pubmed/27154293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0877-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak